Benitec Biopharma Inc (BNTC)

Benitec Biopharma's stock price has decreased by 16.09% in the past six months and 20.68% in the past month. H.C. Wainwright lowered its price target for BNTC from $35 to $32 due to dilution from recent equity offerings, while reaffirming a "Buy" rating. Benitec Biopharma provided positive interim clinical study results for its BB-301 Phase 1b/2a clinical trial and received FDA Fast Track Designation for BB-301 on November 3, 2025. The company also announced its full-year 2025 financial results and provided an operational update on September 22, 2025.

Historically, buying BNTC stock in March has shown the highest probability of a positive return (66.67%), while June has demonstrated the lowest probability of a positive return (27.27%).

Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) platform. This platform combines RNA interference with gene therapy to silence disease-causing genes and, in some cases, deliver wild-type replacement genes. The company's lead program, BB-301, targets Oculopharyngeal Muscular Dystrophy (OPMD), and it is also engaged in research for Chronic Hepatitis B.

Benitec Biopharma, Inc. is headquartered in Hayward, California, United States.

Benitec Biopharma maintains a positive brand reputation, particularly within the analyst community, with a "Strong Buy" consensus rating. Analysts view its "Silence and Replace" technology as a revolutionary approach in gene therapy. The company emphasizes its commitment to advancing novel genetic medicines and highlights its close collaboration with families, clinical researchers, and healthcare providers in the development of its BB-301 program.

Benitec Biopharma Inc. is primarily owned by institutional shareholders (86.42%), followed by Benitec Biopharma insiders (10.84%), and retail investors (2.74%). Major institutional owners include Suvretta Capital Management, LLC, Janus Henderson Group Plc, and Franklin Resources Inc.